ARWR: Arrowhead Pharmaceuticals Inc. Stocks News on June 2, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

ARWR

Business Wire

3 hours ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

ARWR

Business Wire

4 days ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

ARWR

Argus Research

13 days ago

ARWR: Raising target price to $13.00

ARWR

Zacks Small Cap Research

18 days ago

ARWR: Multiple Value Drivers for Long-Term Growth…

ARWR

MT Newswires

19 days ago

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating

ARWR

Argus Research

20 days ago

ARWR: Rating decreased to a SELL

ARWR

MT Newswires

20 days ago

RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating

ARWR

GuruFocus.com

20 days ago

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...

ARWR

MT Newswires

21 days ago

Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours

ARWR

Associated Press Finance

21 days ago

Arrowhead Research: Fiscal Q2 Earnings Snapshot

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

ARWR

Business Wire

21 days ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

ARWR

Zacks

a month ago

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

ARWR

Business Wire

a month ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

ARWR

Argus Research

a month ago

ARWR: What does Argus have to say about ARWR?

ARWR

Insider Monkey

a month ago

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

ARWR

Business Wire

a month ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

ARWR

Argus Research

a month ago

ARWR: Lowering target price to $13.00

ARWR

Argus Research

2 months ago

ARWR: Raising target price to $14.00

ARWR

MT Newswires

2 months ago

Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

ARWR

Business Wire

2 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

ARWR

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 04/14/2025

ARWR

MT Newswires

2 months ago

Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,533,337, According to a Recent SEC Filing

ARWR

Argus Research

2 months ago

ARWR: Lowering target price to $10.00

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWR

Business Wire

2 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWR

Argus Research

2 months ago

ARWR: Lowering target price to $13.00

ARWR

Argus Research

2 months ago

ARWR: Rating increased to a HOLD

ARWR

Simply Wall St.

2 months ago

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company

ARWR

MT Newswires

3 months ago

Arrowhead Pharmaceuticals Insider Sold Shares Worth $774,975, According to a Recent SEC Filing

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

ARWR

Benzinga

3 months ago

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

ARWR

MT Newswires

3 months ago

Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

ARWR

Business Wire

3 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

ARWR

MT Newswires

3 months ago

Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

ARWR

Business Wire

3 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

ARWR

Argus Research

3 months ago

ARWR: Lowering target price to $14.00

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

ARWR

Business Wire

3 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

ARWR

Argus Research

3 months ago

ARWR: What does Argus have to say about ARWR?

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

ARWR

Business Wire

3 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

ARWR

Insider Monkey

3 months ago

Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now

ARWR

Argus Research

3 months ago

ARWR: Raising target price to $16.00

ARWR

MT Newswires

4 months ago

B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating

ARWR

Zacks Small Cap Research

4 months ago

ARWR: Multiple Catalysts Ahead in 2025…

Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

ARWR

Simply Wall St.

4 months ago

Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

ARWR

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

ARWR

GuruFocus.com

4 months ago

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...

ARWR

MT Newswires

4 months ago

Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines -- Shares Down After Hours

ARWR

Associated Press Finance

4 months ago

Arrowhead Research: Fiscal Q1 Earnings Snapshot

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

ARWR

Business Wire

4 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

ARWR

MT Newswires

4 months ago

Arrowhead Closes Licensing, Collaboration Agreement With Sarepta

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

ARWR

Business Wire

4 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

ARWR

Argus Research

4 months ago

ARWR: What does Argus have to say about ARWR?

ARWR

Argus Research

4 months ago

ARWR: Rating decreased to a SELL

ARWR

MT Newswires

4 months ago

Guidewire Software to Join S&P MidCap 400, Arrowhead Pharmaceuticals to Move to S&P SmallCap 600

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

ARWR

PR Newswire

4 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

ARWR

Business Wire

4 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

ARWR

Argus Research

4 months ago

ARWR: Raising target price to $21.00

ARWR

MT Newswires

4 months ago

Sector Update: Health Care Stocks Rise Premarket Tuesday

ARWR

MT Newswires

5 months ago

Arrowhead Pharmaceuticals' New Drug Application for Plozasiran Accepted by FDA

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

ARWR

Business Wire

5 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

ARWR

Argus Research

5 months ago

ARWR: Lowering target price to $19.00

Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial

ARWR

Clinical Trials Arena

5 months ago

Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial

ARWR

Argus Research

5 months ago

ARWR: Lowering target price to $16.00

ARWR

MT Newswires

5 months ago

Arrowhead Pharmaceuticals Doses First Patients in Trial of Potential Obesity Drug

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

ARWR

Business Wire

5 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

ARWR

MT Newswires

5 months ago

Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing

ARWR

Business Wire

5 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

ARWR

Argus Research

6 months ago

ARWR: Lowering target price to $18.00

ARWR

MT Newswires

6 months ago

B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

ARWR

Business Wire

6 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

ARWR

Argus Research

6 months ago

ARWR: Lowering target price to $22.00

ARWR

Simply Wall St.

6 months ago

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week

Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment

ARWR

Clinical Trials Arena

6 months ago

Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment

ARWR

Argus Research

6 months ago

ARWR: Raising target price to $23.00

ARWR

MT Newswires

6 months ago

HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating

ARWR

MT Newswires

6 months ago

Arrowhead Pharmaceuticals Files Request to Initiate Phase 1/2a Trial of Obesity Treatment

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

ARWR

Business Wire

6 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

ARWR

Zacks Small Cap Research

6 months ago

ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

ARWR

Business Wire

6 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead price target lowered to $24 from $27 at Bernstein

ARWR

TipRanks

6 months ago

Arrowhead price target lowered to $24 from $27 at Bernstein

Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance

ARWR

TipRanks

6 months ago

Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance

Sarepta price target lowered to $202 from $205 at Needham

ARWR

TipRanks

6 months ago

Sarepta price target lowered to $202 from $205 at Needham

ARWR

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

ARWR

Zacks

6 months ago

SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies

Arrowhead Stock Rockets 16% After Major Licensing Deal

ARWR

GuruFocus.com

6 months ago

Arrowhead Stock Rockets 16% After Major Licensing Deal

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

ARWR

TipRanks

6 months ago

Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board

ARWR

TipRanks

6 months ago

Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board

Arrowhead and Sarepta link for rare genetic disease treatments

ARWR

Pharmaceutical Technology

6 months ago

Arrowhead and Sarepta link for rare genetic disease treatments

ARWR

GuruFocus.com

6 months ago

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ...

ARWR

MT Newswires

6 months ago

Arrowhead Pharmaceuticals Fiscal Q4 Loss Widens, Revenue Declines

Arrowhead Pharma, Sarepta TX ink new gene therapy deal

ARWR

Yahoo Finance Video

6 months ago

Arrowhead Pharma, Sarepta TX ink new gene therapy deal

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

ARWR

Business Wire

6 months ago

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

ARWR

MT Newswires

6 months ago

Sector Update: Health Care

ARWR

MT Newswires

6 months ago

Top Midday Gainers

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

ARWR

Investor's Business Daily

6 months ago

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

ARWR

Investor's Business Daily

6 months ago

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

ARWR

MT Newswires

6 months ago

Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

ARWR

Business Wire

6 months ago

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

ARWR

Insider Monkey

6 months ago

Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

ARWR

MT Newswires

6 months ago

Arrowhead Files Plozasiran New Drug Application in Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

ARWR

Business Wire

6 months ago

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

ARWR

Business Wire

6 months ago

Latest Arrowhead Pharmaceuticals Inc. (ARWR) News on June 2, 2025

Share on Social Networks: